Partner deck (PDF)

Rewriting the story of kidney disease

Canada's dedicated kidney licensing and commercialization partner, closing the gap between global innovation and Canadian patients.

Discover Kidnera

Mission & Vision

Why we exist.

Mission

To accelerate access to breakthrough kidney therapies for patients in Canada by bringing global innovations to market through licensing, scientific and regulatory expertise, and collaboration with a national nephrology network.

Vision

A future where Canada leads in access to kidney innovation, and every breakthrough opens new possibilities for people living with kidney disease.

The Team

The right team for this work.

Portrait of Jeff Marchand

Jeff Marchand

Chief Commercial Officer

  • Pharmaceutical executive, with > 25 years commercial leadership expertise in Canadian healthcare market
  • Led numerous first in class launches across multiple therapeutic areas including five in nephrology
  • Developed and executed sustainable growth and expansion strategies via global licensing agreements.
  • Leadership experience across the full range of product lifecycle including pre-marketing to post loss-of-exclusivity.
  • Extensive network across the entire Canadian kidney community.
LinkedIn
Portrait of Lee Courchesne

Lee Courchesne

Chief Executive Officer

  • Founder of Canada's largest and most successful medical education company.
  • Pharmaceutical industry experience across key roles and strategic partnerships.
  • Direct experience in pharmaceutical co-distribution via Ilanga partnership.
  • Deep relationships with nephrologists and specialty HCPs across Canada.
  • Established nephrology education network enabling rapid clinical engagement.
  • Proven ability to build and scale healthcare organizations.
LinkedIn
Portrait of Dr. Navdeep Tangri

Dr. Navdeep Tangri

Chief Medical Advisor

  • Physician, scientist and entrepreneur; 15+ years leading research orgs.
  • Experienced in US regulatory discussions and Canadian HTA.
  • Leading KOL in nephrology across Canada and internationally.
  • Deep expertise in CKD and kidney disease progression.
  • Bridges clinical insight with commercial strategy.
  • Strong connections throughout the Canadian kidney care network.
LinkedIn

The opportunity

A gap the size of a nation.

3M+

Canadians living with chronic kidney disease

$3.5B

Canadian specialty pharmaceutical market

85%

Novel renal therapies not yet in Canada

Many biotechs are developing transformative renal therapies - yet many never reach Canadian patients. Health Canada pathways, provincial payer complexity, and the absence of a dedicated renal commercialization partner create a persistent gap. Kidnera exists to close it.

See our model →

Our model

A turnkey Canadian renal licensing partner.

  1. 01

    License

    Exclusive Canadian under license rights from international biotech partner.

  2. 02

    Regulatory

    Health Canada submission strategy, filings, and negotiation.

  3. 03

    Medical Affairs

    Key Opinion Leader engagement, advisory boards, Medical Education, and evidence generation.

  4. 04

    Market Access

    Develop pricing strategy to support submission to public and private drug plans

  5. 05

    Commercial

    Physician education, national distribution, and patient support.

From licence to patient, one Canadian partner.

Why Canada, why now

A top-10 market with a unique opportunity for growth.

38M

Canadians covered by public drug plans

10

Provinces, each a structured formulary

~24mo

Typical Health Canada review timeline

$0

Revenue earned in Canada by international biotechs today

= the untapped upside

1

Predictable Revenue

Coordinated public reimbursement and pricing processes support contracted, recurring revenue once listed.

2

Global Credibility

Canadian approval strengthens international credibility and supports expansion into the US and Europe.

3

Efficient Regulatory Path

Health Canada accepts ICH-aligned data; NDS can proceed in parallel with or shortly after an FDA filing.

4

Clinical Interest

Canadian nephrologists actively seek access to therapies approved or in late-stage development in the US.

5

First-Mover Advantage

No dedicated renal licensing platform exists in Canada today - the window for early advantage is open now.

6

National Network

Deep relationships across Canada's nephrology community provide direct access to KOLs, centres, and stakeholders.

What We Bring

You focus on innovation.
We focus on Canada.

Clinical Credibility

Dr. Tangri's national KOL standing opens doors across every major Canadian nephrology centre. Advisory boards, investigator-initiated studies, and CME programs are immediately accessible.

Regulatory Expertise

We navigate Health Canada NDS/SNDS filings, CDR submissions, and pCPA negotiations - turning complex Canadian payer structures into predictable revenue timelines.

Commercial Execution

Jeff Marchand's specialty pharma launch experience covers the full arc - from pre-launch HCP engagement to post-listing demand generation and patient support.

Network & Reach

Lee Courchesne's medical education infrastructure provides unmatched reach into Canadian HCPs. We don't need to build relationships - we already have them.

Singular Focus

We are not a generalist partner across ten therapeutic areas. We are renal specialists. Your asset gets our full attention - not a line item in a broad portfolio.

Aligned Incentives

Our licensing model means our success is tied directly to yours. We are motivated partners - not a fee-for-service operator.

Partnership Structure

Proposed partnership structure.

Kidnera takes on
  • All Canadian regulatory filing costs and strategy
  • Health Canada and CADTH submissions
  • KOL engagement and medical affairs program
  • Provincial market access and pCPA negotiation
  • Commercial launch infrastructure
  • Patient support and access programs
  • Post-market safety monitoring in Canada
Partner provides
  • Exclusive Canadian licensing rights
  • Clinical data package for submission
  • Ongoing pharmacovigilance support
  • Manufacturing and supply chain / distribution

Next steps

The right team.
The right country.
The right time.

  1. STEP 01

    Execute mutual NDA to enable full data exchange.

  2. STEP 02

    Share clinical package and target Canadian label discussion.

  3. STEP 03

    Term sheet for exclusive Canadian license.

  4. STEP 04

    Regulatory timeline and market access planning workshop.

Contact

Let's talk about your renal asset.

info@kidnera.ca

Lee Courchesne

Chief Executive Officer

lee@kidnera.ca →

Jeff Marchand

Chief Commercial Officer

jeff@kidnera.ca →

Dr. Navdeep Tangri

Chief Medical Advisor

navdeep@kidnera.ca →